US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

LB Pharmaceuticals / Equity Capital Markets

<ul>
<li>LB Pharmaceuticals (LBRX) priced an upsized IPO of 19.0 million shares at the midpoint of the range, $15.00. Shares opened at $19.00, delivering a +26.7% gain at first trade.</li>
<li>Existing shareholders in previous rounds were likely anchoring the stock and providing stabilization in its debut.</li>
<li>We expect short-term trading to follow the broader biotech sector trend, with catalysts tied directly to clinical and regulatory developments.</li>
</ul>


LB Pharmaceuticals (LBRX) priced an upsized IPO of 19.0 million shares at the midpoint of the range, $15.00. Shares opened at $19.00, delivering a +26.7% gain at first trade.
Existing shareholders in previous rounds were likely anchoring the stock and providing stabilization in its debut.
We expect short-term trading to follow the broader biotech sector trend, with catalysts tied directly to clinical and regulatory developments.


LB Pharmaceuticals Inc. (LBRX): Strong Open, Schizophrenia Biotech Finds Early Momentum

<ul>
<li>LB Pharmaceuticals (LBRX US) launched on Monday (9/8) for a quick Thursday (9/11) debut. </li>
<li>Deep Track (19.9%), Vida Ventures (16.0%), Pontifax (12.0%) and TCG Crossover (12.0%) are all stakeholders in this company.</li>
<li>The abbreviated roadshow and the insider-driven nature of this biotech IPO suggest it will involve only a limited number of participants.</li>
</ul>


LB Pharmaceuticals (LBRX US) launched on Monday (9/8) for a quick Thursday (9/11) debut. 
Deep Track (19.9%), Vida Ventures (16.0%), Pontifax (12.0%) and TCG Crossover (12.0%) are all stakeholders in this company.
The abbreviated roadshow and the insider-driven nature of this biotech IPO suggest it will involve only a limited number of participants.


LB Pharmaceuticals Inc. (LBRX): Clubby Deal Expected in Thursday's Schizophrenia Biotech IPO

<ul>
<li>LB Pharmaceuticals is offering 16.7 million shares at $14-$16 equating to a market cap of $281m-$322m.</li>
<li>According to guidance that the deal is well-oversubscribed at launch from a comprehensive testing-the-waters meetings.</li>
<li>Investor sentiment toward the subsector remains constructive, and the company’s lead candidate is entering Phase III with a solid track record of clinical data.</li>
</ul>


LB Pharmaceuticals is offering 16.7 million shares at $14-$16 equating to a market cap of $281m-$322m.
According to guidance that the deal is well-oversubscribed at launch from a comprehensive testing-the-waters meetings.
Investor sentiment toward the subsector remains constructive, and the company’s lead candidate is entering Phase III with a solid track record of clinical data.


LB Pharmaceuticals Inc. (LBRX): Schizophrenia Biotech Sets Terms, Readies for Same-Week Debut

<ul>
<li>Their product candidate, LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms.</li>
<li>The largest holder is Deep Track Biotechnology Master Fund, Ltd., controlling 16.7 million shares, or 19.6% of the company.</li>
<li>There has not been a biotech IPO since Aardvark Therapeutics in mid February. This biotech may be more well-received given that its lead product candidate is in Phase III.</li>
</ul>


Their product candidate, LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms.
The largest holder is Deep Track Biotechnology Master Fund, Ltd., controlling 16.7 million shares, or 19.6% of the company.
There has not been a biotech IPO since Aardvark Therapeutics in mid February. This biotech may be more well-received given that its lead product candidate is in Phase III.


LB Pharmaceuticals Inc. (LBRX): Peeking at the IPO Prospectus of Schizophrenia Product Candidate Bio

MapLight Therapeutics / Equity Capital Markets

<ul>
<li>The company that describes itself as a biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system.</li>
<li>Morgan Stanley, Jefferies, Leerink Partners, Stifel are the bookrunners on this IPO.</li>
<li>Their lead product candidate, ML-007C-MA, is currently in a Phase II trial.</li>
</ul>


The company that describes itself as a biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system.
Morgan Stanley, Jefferies, Leerink Partners, Stifel are the bookrunners on this IPO.
Their lead product candidate, ML-007C-MA, is currently in a Phase II trial.


Maplight Therapeutics (MPLT): Peeking at the IPO Prospectus of Biotech Treating CNS Diseases

United States

LB Pharmaceuticals Inc is a biopharmaceutical company. The Company develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. LB Pharmaceuticals serves operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

LB Pharmaceuticals (LBRX US)

LB Pharmaceuticals Inc. (LBRX): Strong Open, Schizophrenia Biotech Finds Early Momentum

LB Pharmaceuticals (LBRX) IPO priced at $15.00, opened at $19.00 with +26.7% gain. Existing shareholders likely providing stability.

IPO Boutique

LB Pharmaceuticals Inc. (LBRX): Clubby Deal Expected in Thursday's Schizophrenia Biotech IPO

LB Pharmaceuticals (LBRX US) launched on Monday for a Thursday debut and is likely to have key stakeholders anchor the IPO

IPO Boutique

LB Pharmaceuticals Inc. (LBRX): Schizophrenia Biotech Sets Terms, Readies for Same-Week Debut

LB Pharmaceuticals is offering 16.7 million shares at $14-$16, with a market cap of $281m-$322m and will debut on Thursday (9/11).

IPO Boutique

LB Pharmaceuticals Inc. (LBRX): Peeking at the IPO Prospectus of Schizophrenia Product Candidate Bio

LB-102, a Phase 3-ready oral treatment for acute schizophrenia, has potential for success in the biotech market with significant backing from Deep...

IPO Boutique

Maplight Therapeutics (MPLT): Peeking at the IPO Prospectus of Biotech Treating CNS Diseases

Biopharmaceutical company focused on CNS disorders set to go public with lead product in Phase II trial, backed by top bookrunners.

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

LB Pharmaceuticals Inc. (LBRX): Strong Open, Schizophrenia Biotech Finds Early Momentum

​LB Pharmaceuticals (LBRX) IPO priced at $15.00, opened at $19.00 with +26.7% gain. Existing shareholders likely providing stability.

IPO Boutique

LB Pharmaceuticals Inc. (LBRX): Clubby Deal Expected in Thursday's Schizophrenia Biotech IPO

​LB Pharmaceuticals (LBRX US) launched on Monday for a Thursday debut and is likely to have key stakeholders anchor the IPO

IPO Boutique

LB Pharmaceuticals Inc. (LBRX): Schizophrenia Biotech Sets Terms, Readies for Same-Week Debut

​LB Pharmaceuticals is offering 16.7 million shares at $14-$16, with a market cap of $281m-$322m and will debut on Thursday (9/11).

IPO Boutique

LB Pharmaceuticals Inc. (LBRX): Peeking at the IPO Prospectus of Schizophrenia Product Candidate Bio

​LB-102, a Phase 3-ready oral treatment for acute schizophrenia, has potential for success in the biotech market with significant backing from Deep...

IPO Boutique

Maplight Therapeutics (MPLT): Peeking at the IPO Prospectus of Biotech Treating CNS Diseases

​Biopharmaceutical company focused on CNS disorders set to go public with lead product in Phase II trial, backed by top bookrunners.

IPO Boutique

LB Pharmaceuticals (LBRX) IPO priced at $15.00, opened at $19.00 with +26.7% gain. Existing shareholders likely providing stability.

LB Pharmaceuticals (LBRX US) launched on Monday for a Thursday debut and is likely to have key stakeholders anchor the IPO

LB Pharmaceuticals is offering 16.7 million shares at $14-$16, with a market cap of $281m-$322m and will debut on Thursday (9/11).

LB-102, a Phase 3-ready oral treatment for acute schizophrenia, has potential for success in the biotech market with significant backing from Deep...

Biopharmaceutical company focused on CNS disorders set to go public with lead product in Phase II trial, backed by top bookrunners.